Navigation Links
Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
Date:9/10/2007

elease which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the protocol will not be approved, the risk that the company will experience delays or difficulties in enrolling patients in the study, and the risk that the results from this trial will not be consistent with the results of prior trials or pre-clinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the annual report on Form 10-K for the year ended April 30, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , 1. September 2015 In nur ... 2.500 Mitarbeitern hat die SHL Group schnell weltweit ... und rapides Wachstum auf dem Markt der ... Produktivität und das Management von SHL wieder. ... SHL ist weltweit führend in Design und Herstellung ...
(Date:9/1/2015)... 31, 2015 Research and Markets ( ... "Introduction to Veterinary Pharmacovigilance (London, UK - ... This course has been designed to ... those concerned with Veterinary Pharmacovigilance. New entrants, support ... a better understanding of veterinay drug safety will ...
(Date:9/1/2015)... 1, 2015 Egalet Corporation (Nasdaq: ... company focused on discovering, developing, and commercializing innovative ...  presenting scientific data on SPRIX ® (ketorolac ... morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, ... 2015 to be held September 8 to ...
Breaking Medicine Technology:SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2Introduction to Veterinary Pharmacovigilance Seminar (London, UK - September 23-24) 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 3Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 4Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 5Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 6
(Date:9/1/2015)... ... September 01, 2015 , ... ... Extension Vending Machine,” is still strongly maintaining her firm’s success in the hair ... tools. In her upcoming city-to-city tour, Ellis will be providing “Look and learn” ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Jerry Segal Classic to benefit the patients ... Valley Country Club in Lafayette Hill, PA. Over the past 26 years, the Classic, ... programs and services designed to support patients and their families during their time at ...
(Date:9/1/2015)... ... 01, 2015 , ... e-Spirit Inc., a leading supplier of ... Content Management System with new capabilities and enhancements designed to support the recently ... be well on their way to achieving digital transformation with less time and ...
(Date:9/1/2015)... ... , ... The FSH Society , the Massachusetts-based charity that has transformed ... the beneficiary of a collection of fundraising events this fall. From Boston to Los ... Society and further FSHD research. , The list of 2015 fall events ...
(Date:9/1/2015)... ... 01, 2015 , ... METTLER TOLEDO has announced an upcoming ... requirements“ , featuring Ed Szczesny (Quality Assurance, Rhodes Pharmaceuticals) as guest presenter. This ... , Calibration, qualification, and the appropriate level of routine testing for laboratory ...
Breaking Medicine News(10 mins):Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2
... Teen the Chance to be drawn into a ... Batman comic ... living a dual life is no easy task. Along with exercise and,eating ... after a night spent defeating Gotham City,s most evil villains., (Photo: ...
... to Retire from Company, INDIANAPOLIS, May 28 ... of its Operations, Technology and,Government Services unit based ... executive officer of that organization. Effective July 1, ... will not be replacing him,in that role., ...
... $60 million over 11 years , , WEDNESDAY, May 28 (HealthDay ... belts significantly reduces injuries to the brain, face, spine and ... rates, injury severity and hospital-acquired infections among crash patients, says ... use of air bags could reduce the use of resources ...
... A study released today reveals a cellular mechanism involved ... issue of The Journal of Neuroscience, shows that gabapentin, ... reduces alcohol intake in alcohol-dependent rats by normalizing chemical ... abuse. , The central amygdala, a part of the ...
... NEW YORK, May 28 Responding to the decline ... the past four trading days,Robin Smith, CEO, NeoStem said, ... would lead to the sudden decline in our share ... 21, 2008, we received a,private placement financing in a ...
... CHUM and MUHC migration to complete electronic records, ... Solutions, Inc. (Nasdaq: STRM ) and Emergis ... an integrated document management and,workflow solution at the ... Montreal (CHUM) and the McGill University,Health Centre (MUHC). ...
Cached Medicine News:Health News:Batman Takes on Gotham City With a Little Help From Milk 2Health News:WellPoint Announces Realignment of Operations, Technology and Government Services Unit 2Health News:Air Bags-Seat Belts Cut Injuries, Deaths, Costs 2Health News:New study reveals brain cell mechanism of alcohol dependence 2Health News:NeoStem, Inc. Comments on Recent Selling Pressure 2Health News:Streamline Health's Document Management Solution Integrated into Oacis, Allowing Clinicians to Access Patients' Information - Either Scanned or Electronic 2Health News:Streamline Health's Document Management Solution Integrated into Oacis, Allowing Clinicians to Access Patients' Information - Either Scanned or Electronic 3Health News:Streamline Health's Document Management Solution Integrated into Oacis, Allowing Clinicians to Access Patients' Information - Either Scanned or Electronic 4Health News:Streamline Health's Document Management Solution Integrated into Oacis, Allowing Clinicians to Access Patients' Information - Either Scanned or Electronic 5
Kleinert-Kutz Single Skin Hook, Large...
Designated most popular model or size....
Gillies (Converse) Skin Hook, small hook size....
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
Medicine Products: